diabetes and dialysis
Conditions
Interventions
HD5:Henagliflozin 5 mg qd+HD
HD10:Henagliflozin 10 mg qd+HD
PD5:Henagliflozin 5 mg qd+PD
PD10:Henagliflozin 10 mg qd+PD
Sponsors
Renji Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand the present study, and agree and sign informed consent; 2. Aged 18-75 years at the screening; 3. Hemodialysis three times/week and regular hemodialysis>= 3 month; 4. Kt/V of single dialysis was more than 1.0 or URR more than 60% in 3 month; 5. CAPD or DAPD patients, more than 3 month; 6. Kt/V more than 1.7 in 6 month for PD patients; 7. Type 2 Diabetes.
Exclusion criteria
Exclusion criteria: 1. Hypocaemia events more than 2 times in 4 weeks; 2. Hb lower than 7 g/dL or more than 14 g/dL; 3. BPC lower than 5x10^9/L; 4. Liver function (ALT or AST) is three times the upper the normal; 5. Patients with active infectious disease; 6. Patients with cancer; 7. Patients with ketoacidosis in 3 month; 8. Patients with genitourinary system infection; 9. Allergy for henagliflozin; 10. Pregnant and lactating women; 11. Participating in other intervention studies; 12. The investigator judged that the condition of the subjects was not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Henagliflozin concentration; | — |
Secondary
| Measure | Time frame |
|---|---|
| events of hypocaemia and ketoacidosis; | — |
Countries
China
Contacts
Public ContactLeyi Gu
Renji Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed